CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Show more...
CEO
Dr. Pinchas Cohen Dean, M.D., Ph.D.
Karyawan
9
Negara
US
ISIN
US19249J1097
Pencatatan
0 Comments
Bagikan pendapatmu
FAQ
Berapa harga saham CohBar hari ini?▼
Harga saat ini dari CWBR adalah $0.41 USD — turun sebesar -8.89% dalam 24 jam terakhir. Pantau kinerja harga saham CohBar lebih dekat di grafik.
Apa simbol saham CohBar?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham CohBar diperdagangkan dengan simbol CWBR.
Berapa pendapatan CohBar tahun lalu?▼
Pendapatan CohBar tahun lalu berjumlah 0 USD.
Berapa pendapatan bersih CohBar tahun lalu?▼
Pendapatan bersih CWBR untuk tahun lalu adalah -12.18M USD.
Berapa jumlah karyawan CohBar?▼
Per April 04, 2026, perusahaan memiliki 9 karyawan.
CohBar berada di sektor apa?▼
CohBar beroperasi di sektor Health Care.
Kapan CohBar menyelesaikan split saham?▼
Pemecahan saham terakhir CohBar terjadi pada September 23, 2022 dengan rasio 1:30.